Moderna and Merck's mRNA cancer vaccine succeeds in Phase 3 melanoma trial

Phase 3 Trial Success for mRNA Cancer Vaccine

Pharmaceutical companies Moderna and Merck reported that their mRNA-based cancer vaccine, intismeran (mRNA-4157), demonstrated effectiveness in a Phase 3 clinical trial for melanoma. This vaccine is designed to be individually tailored to target a patient's specific cancer mutations. The trial focused on patients with stage IIB–IV melanoma, a severe form of skin cancer.

Trial Design and Combination Therapy

The Phase 3 trial included 1,137 patients whose melanoma had been surgically removed. Participants were randomized to receive either a combination of the mRNA vaccine with Merck's Keytruda, or Keytruda alone. Both groups received treatment for approximately one year. The study was placebo-controlled and double-blind, ensuring neither patients nor doctors knew the assigned treatment.

Improved Survival Outcomes

Based on an interim analysis, the combination therapy of the mRNA vaccine and Keytruda extended "recurrence-free survival" (RFS) and "distant metastasis-free survival" (DMFS). RFS measures the time without cancer returning, while DMFS measures the time without cancer returning and spreading to other body parts. The companies stated these extensions were statistically significant and clinically meaningful, with full data to be presented at an upcoming medical conference.

Prior Phase 2 Results

Data from a five-year Phase 2 trial, presented in June, indicated a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death for patients receiving the combination therapy. These earlier findings support the potential of the mRNA vaccine in treating melanoma.

Mechanism of Action

The intismeran mRNA vaccine functions by using synthetic mRNA that encodes for up to 34 unique mutations found in a patient's cancer cells. The vaccine production process involves comparing the genetic sequences of a patient's cancer cells with healthy cells to identify cancer-specific mutations. This allows the immune system to differentiate and target cancer cells.

Implications for Cancer Therapy

This success represents a significant milestone for both mRNA vaccine technology and individualized cancer-targeting medicines. If these results hold, it could establish a new paradigm in cancer treatment, particularly for melanoma, by leveraging the body's immune system to specifically combat cancer cells based on their unique genetic profiles.